CT/NG 测试市场 - 按产品类型、测试类型、技术、最终用途和预测，2024 年至 2032 年

CT/NG Testing Market - By Product Type, By Test Type, By Technology, By End-use & Forecast, 2024 - 2032

出版日期: 2024年05月07日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

简介目录

「由于全球沙眼衣原体(CT) 感染盛行率不断上升，预计2024 年至2032 年CT/NG 检测市场规模的复合年增长率将达到7.1%。根据CDC 数据，2022 年报告的沙眼衣原体感染病例总数为1,649,716 例CT 是全球最常见的细菌性传播感染之一，性行为改变、意识不足和医疗保健障碍等因素导致发病率上升，因为医疗保健系统优先考虑早期发现和治疗以减轻传播。的发展，对有效诊断解决方案的需求持续上升。

越来越多地采用基于聚合酶链反应 (PCR) 的检测方法是主要的市场趋势。 PCR 技术透过扩增遗传物质，在检测沙眼衣原体 (CT) 和淋病奈瑟菌 (NG) 感染方面具有高灵敏度和特异性。这种方法因其识别低水平感染的准确性而受到青睐，推动其在临床诊断中的广泛应用。随着医疗保健提供者优先考虑精确和快速的检测解决方案，基于 PCR 的检测方法继续受到关注，为市场成长做出了重大贡献。

CT/NG 测试产业根据产品、测试类型、技术、最终用途和地区进行分类。

到 2032 年，仪器/分析仪领域将快速成长，因为它们为医疗保健专业人员提供了准确诊断的可靠工具。有一系列产品，包括核酸扩增测试（NAAT）、快速诊断测试（RDT）和分子诊断仪器。这些仪器旨在检测 CT 和 NG 细菌的特定遗传物质，从而能够及早、准确地识别感染。製造商正在专注于开发用户友好的设备，这些设备整合了自动化功能，并为医疗保健提供者提供具有成本效益的解决方案。

到 2032 年，聚合酶链反应 (PCR) 领域将以相当快的速度增长，因为它在检测细菌 DNA 方面提供了高灵敏度和特异性。基于 PCR 的检测方法因其能够扩增微量遗传物质而被广泛采用，使其适用于低水平感染。随着多重 PCR 等技术的进步，该技术不断发展，可以在单一样本中同时检测多种病原体。基于 PCR 的测试因其可靠性和稳健的性能而在临床环境中受到青睐，对市场成长轨迹做出了重大贡献。

在有利的医疗政策、对性传播感染预防的高度认识以及强大的医疗基础设施的推动下，欧洲 CT/NG 检测市场规模将在 2024 年和 2032 年稳步扩大。由于政府积极采取措施降低性传染感染流行率，德国、法国和英国等国家越来越多地采用 CT/NG 检测。对公共卫生和疾病监测的高度重视进一步支持了市场成长。此外，诊断技术的技术进步和主要参与者的存在有助于欧洲在 CT/NG 检测市场的领导地位。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Abbott Laboratories
Becton, Dickinson and Company
binx health, inc.
Bioneer Corporation
Bio-Rad Laboratories, Inc.
Cepheid
ELITech Group
Genetic Signatures
Hologic, Inc.
Meridian Bioscience
Qiagen
Roche
Seegene, Inc.
Thermo Fisher Scientific, Inc.
VIRCELL S.L.

简介目录

Product Code: 9397

"The CT/NG Testing Market size is anticipated to infer 7.1% CAGR during 2024-2032, driven by the escalating prevalence of chlamydia trachomatis (CT) infections worldwide. According to CDC, in 2022, the reported cases of chlamydia trachomatis infection totaled 1,649,716. CT is one of the most common bacterial STIs globally, affecting millions annually. Factors such as changing sexual behaviors, inadequate awareness, and barriers to healthcare access contribute to the rising incidence rates. As healthcare systems prioritize early detection and treatment to mitigate the spread of CT, the demand for effective diagnostic solutions continues to rise.

The increasing adoption of Polymerase Chain Reaction (PCR)-based assays is a major market trend. PCR technology offers high sensitivity and specificity in detecting chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) infections by amplifying genetic material. This method is favored for its accuracy in identifying low-level infections, driving its widespread integration in clinical diagnostics. As healthcare providers prioritize precise and rapid testing solutions, PCR-based assays continue to gain traction, contributing significantly to market growth.

The CT/NG testing industry is classified based on product, test type, technology, end-use, and region.

The instruments/analyzers segment will grow rapidly through 2032, as they provide healthcare professionals with reliable tools for accurate diagnosis. There is a range of products including nucleic acid amplification tests (NAATs), rapid diagnostic tests (RDTs), and molecular diagnostic instruments. These instruments are designed to detect specific genetic material from CT and NG bacteria, enabling early and precise identification of infections. Manufacturers are focusing on developing user-friendly devices that integrate automation and provide cost-effective solutions to healthcare providers.

Polymerase Chain Reaction (PCR) segment will grow at a decent rate through 2032, as it offers high sensitivity and specificity in detecting bacterial DNA. PCR-based assays are widely adopted due to their ability to amplify minute amounts of genetic material, making them suitable for low-level infections. The technology continues to evolve with advancements such as multiplex PCR, which allows the simultaneous detection of multiple pathogens in a single sample. PCR-based tests are preferred in clinical settings for their reliability and robust performance, contributing significantly to the market growth trajectory.

Europe CT/NG testing market size will expand at a steady pace during 2024 and 2032, driven by favorable healthcare policies, high awareness levels regarding STI prevention, and robust healthcare infrastructure. Countries like Germany, France, and the UK are witnessing increasing adoption of CT/NG testing due to proactive government initiatives aimed at reducing STI prevalence. The strong emphasis on public health and disease surveillance further supports market growth. Additionally, technological advancements in diagnostic techniques and the presence of key players contribute to Europe's leadership position in the CT/NG testing market."

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of sexually transmitted infections (STIs)
  - 3.2.1.2 Growing awareness and screening programs
  - 3.2.1.3 Advancements in testing technologies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Social stigma and under-reporting
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Consumables
5.3 Instruments/Analyzers

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Laboratory testing
6.3 Point-of-care (POC) testing

Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Isothermal nucleic acid amplification technology
7.3 Polymerase chain reaction
7.4 Immunodiagnostics
7.5 Other technologies

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals & clinics
8.3 Diagnostic laboratories
8.4 Home care setting
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa